Month: July 2020

JSC Olainfarm hereby provides a comment to certain statements mentioned in an article in newspaper Diena.Chairperson of the Board of JSC Olainfarm Jeroen Weites:“These are rumours. JSC Olainfarm is not currently planning on selling any daughter companies, and no such decisions have been made. Given the Olainfarm Group’s ambitious growth plans and the new five-year business strategy that is being developed, it was important for the company to understand the current asset value of its daughter companies. JSC Olainfarm has signed an agreement with one of the auditors of the Big Four, who has been instructed to perform an asset evaluation. It has no other underlying causes. In addition, JSC Olainfarm daughter companies have recently undergone changes in the Management Board, and both Latvijas Aptieka Ltd and Tonus Elast Ltd have new Chairpersons...

Ar šo AS “Olainfarm” sniedz komentāru par laikrakstā Diena izteiktajiem apgalvojumiemAS “Olainfarm” valdes priekšsēdētājs Jerūns Veitess (Jeroen Weites):“Tās ir baumas. AS “Olainfarm” šobrīd neplāno iespēju pārdot meitas uzņēmumus, un nekādi šādi lēmumi nav pieņemti. Ņemot vērā “Olainfarm” grupas ambiciozos izaugsmes plānus un jaunu piecgades biznesa stratēģiju, kas tiek izstrādāta, uzņēmumam bija svarīgi saprast meitas uzņēmumu pašreizējo aktīvu vērtību. AS “Olainfarm” ir noslēgusi līgumu ar vienu no lielā četrinieka auditoriem, kam dots uzdevums veikt aktīvu novērtējumu. Tam nav citi zemūdens akmeņi. Turklāt “Olainfarm” meitas uzņēmumos pavisam nesen ir veiktas izmaiņas valdē, gan SIA “Latvijas Aptieka”, gan SIA “Tonus Elast” ir jauni valdes priekšsēdētāji, apliecinot izaugsmes plānus. Skatīt paziņojumu šeit:https://cns.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=949269&messageId=1195981.Aicinām...

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic PainSale of XERMELO to TerSera to Yield Up to $224 Million in Upfront and Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract CancerSubstantial Debt Reduction, Including Full Repayment of Secured LoanTHE WOODLANDS, Texas, July 30, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development.  In that regard:Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of...

Fort Worth, TX, July 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — ADM Endeavors, Inc. (OTCQB: ADMQ) is pleased to announce that its wholly owned subsidiary, Just Right Products, Inc., has been awarded by the Tarrant County Commissioner’s Court the annual contract as the primary vendor for work uniforms for Tarrant County, Texas.Marc Johnson, CEO of ADM Endeavors, stated that the 1-year contract commenced on July 1, 2020 and should provide a projected revenue in excess of $50,000. Mr. Johnson explained that since being awarded this contract, the Company is now on a bid list for an additional 525 government entities throughout the State of Texas that can participate under this contract and “piggyback” on to the pricing provided by the Company in this contract. This added feature to the award provides the Company significant...

FORT LAUDERDALE, Fla., July 30, 2020 (GLOBE NEWSWIRE) — via NetworkWire – The Movie Studio, Inc. (OTC: MVES) (the “Company”) today announces it has submitted an official application to the U.S. Patent and Trademark Office (USPTO) and trademark protection is pending for the Company’s recognizable name, insignia, phrase and logo.

THE WOODLANDS, Texas and DEERFIELD, Ill., July 30, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon’s rights, title and interest in XERMELO® (telotristat ethyl).  Pursuant to the terms of the agreement, TerSera will pay Lexicon approximately $159 million in cash at closing, which includes a $155 million upfront payment and approximately $4 million for existing inventory.  Lexicon may receive additional development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer.  Additionally, Lexicon will be eligible to receive mid-teens royalties on net...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION BY ANY UNITED STATES NEWS DISTRIBUTION SERVICETORONTO, July 30, 2020 (GLOBE NEWSWIRE) — Quinsam Capital Corporation (CSE: QCA) (“Quinsam” or the “Company”) is pleased to announce its quarterly dividend and the upcoming renewal of its issuer bid. DividendThe Board of Directors of Quinsam has approved the company’s 24th consecutive quarterly dividend.  The dividend is $0.00125 per share ($0.005 per share per year).  The distribution will be paid on August 26, 2020 to shareholders of record on August 10, 2020.  This dividend will be designated as an “eligible dividend” for Canadian income tax purposes. Future quarterly dividends will be subject to Board approval.Issuer Bid UpdateQuinsam announced a normal course issuer bid to purchase...

 GAAP revenue of $274.0 millionNet income of $4.6 millionAdjusted EBITDA of $84.0 millionCash flow from operations of $67.8 millionFree cash flow of $55.9 million Total subscribers on platform were approximately 4.877 million at June 30, 2020BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) — Endurance International Group Holdings, Inc. (NASDAQ: EIGI), a leading provider of cloud-based platform solutions designed to help small and medium-sized businesses succeed online, today reported financial results for its second quarter ended June 30, 2020.“Against a backdrop of significant macro-economic disruption due to the COVID-19 pandemic, we are encouraged by the resilience of small businesses and their drive to adapt.  As we noted in our preliminary update two weeks ago, we see secular demand for our products and services and are pleased...

~ Entered into Exclusive Global License Agreement with CSL Behring for Development and Commercialization of uniQure’s Gene Therapy Candidate for Hemophilia B ~~ Completed First Patient Dosing in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease ~LEXINGTON, Mass. and AMSTERDAM, July 30, 2020 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2020 and highlighted recent progress across its business.“The first half of 2020 has been extremely productive for uniQure with significant achievements across our clinical-stage programs,” stated Matt Kapusta, chief executive officer at uniQure. “The initiation of patient dosing in our Phase I/II study of AMT-130 marked...